Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells and deliver targeted radiation.
Search results for "Cancer"
Hot Dog vs. Hamburger: Why the Burger Wins the Nutritional Battle
Hot dogs and hamburgers are iconic fast-food staples—convenient, filling, and accessible on a busy day. However, both frequently raise concerns...
The Longevity Diet: 8 Essential Plant-Based Proteins to Help You Live Longer
Prioritizing plant-based protein in your daily meals may be one of the simplest ways to support healthy aging and...
Three or More Pregnancies Linked to 36% Higher Postmenopausal Fracture Risk
For women going through menopause, the risk of bone fractures rises sharply. This vulnerability occurs because bone...
Half a Century of Care: How H Plus Yangji Hospital Rose from a Neighborhood Clinic to a Global Gateway
Gwanak-gu in southern Seoul holds the highest concentration of single-person households among young adults in their 20s...
Managing Blood Sugar Without Sacrificing Nutrition: The Best Low-Sugar Summer Fruits
Many people completely eliminate fruit from their diets when trying to manage blood sugar, fearing that natural...
New Non-Invasive MRI Method Visualizes Elusive Liver and Intestinal Lymph Vessels
South Korean researchers have developed a breakthrough MRI technique that images the body’s lymphatic system without an...
Misdiagnosing Low Testosterone: Why Fatigue and Low Libido May Signal Other Serious Medical Conditions
An increasing number of men are turning to male hormone supplements, but medical experts caution against assuming that...
Elevated Phthalate Levels in Newborn Urine Linked to Dramatic Rise in Childhood Atopic Dermatitis
Another study has added to the growing body of evidence that endocrine-disrupting chemicals can cause direct,...
Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology...